ObAdEx, our innovative biotherapy product in development for chronic metabolic diseases associated to obesity, gets labelled by Eurobiomed, the healthtech growth accelerator of South of France.

Eurobiomed highlights our breakthrough and innovative approach as well as our tailored preclinical developmental plan to de-risk critical bioproduction steps before first-in-patients trials.

ExAdEx-Innov is currently leading a fundraising campaign to accelerate ObAdEx development.

To learn more about ObAdEx: https://exadex-innov.com/investors